Actos Bladder Cancer Headlines

Actos Bladder Cancer : Keep your doctor informed if you are experiencing any of the above side effects. There are drugs that can help minimize these con”ditions and make your treatment more comfortable. Luckily, these side effects tend to disappear once you are no longer receiving chemotherapy, and you will gradually feel stronger and become less vulnerable to bleeding or infections.

For invasive bladder cancer, chemotherapy is sometimes given before you have a cystectomy. Sometimes it’s given afterwards. Sometimes it’s not given at all. It depends entirely on the type of tumor you have, where it may have spread, and whether you have another medical condition that might make it difficult for you to tol”erate chemotherapy. Very advanced age can also be a factor in decid”ing whether chemotherapy is appropriate.

The choice of drugs used to treat invasive bladder cancer is similar to the choice in advanced or metastatic disease. If you have invasive transitional cell carcinoma you will probably undergo chemotherapy, as this type of cancer is responsive to either radiotherapy or surgery with chemotherapy, and many stud”ies have examined this type of cancer treatment.

If you have been diagnosed with squamous cell cancer or adeno”carcinoma, the track record for chemotherapy is not so clearly defined. Most physicians don’t recommend chemotherapy as standard treatment in conjunction with cystectomy for these types of cancer. It is, however, quite reasonable for your team to suggest that you look into a clinical trial (for example, one that is exploring the use of chemotherapy) if you have been diagnosed with squamous cell or adenocarcinoma.

More information on Actos Bladder Cancer

Most of the reported trials indicate that the use of single chemother”apy drugs does not have an extensive beneficial effect, but that the use of combinations of three or four chemotherapy drugs can shrink the bladder cancer in around 70 percent of cases and can also improve the cure rate and length of survival. For you as a patient, the information gleaned from these clinical trials means that if you have TCC, your doctors are likely to recom”mend treatment that includes a “cocktail” of several carefully targeted chemotherapy drugs as well as cystectomy or radiotherapy.

In some cancers, such as breast cancer, it is pretty standard practice to give several doses of chemotherapy after surgery, especially for tumors with high-risk pathological features, such as lymph-node involvement. We know of six studies that have looked at this question in bladder cancer, but the results are somewhat inconclusive as to whether chemotherapy is most effective given before or after surgery.

Information from other sources on Actos Bladder Cancer

When radiation is used alone or with chemotherapy there is an increased likelihood that your other organs, such as the prostate and uterus, will remain functional, as does your ability to void urine normally and have sex. The intention when chemotherapy and radio”therapy are given is usually to improve the chances of curing the cancer while preserving the bladder and avoiding the need to remove it surgically. This area is still somewhat controversial; while some physicians believe that this approach is nearly as effective as surgical removal of the bladder, others feel that cystectomy is the best treat”ment The decision depends in part upon the physical fitness of the patient as well as upon the patient’s personal preferences.

The use of radiotherapy doesn’t mean that it is without side effects. There can be scarring of the bladder tissue, and that can reduce the amount of urine your bladder can hold. The result would be an increase in the number of times you have to urinate, which can be irritating, especially at night. You also may experience an increase in bouts of cystitis.

There has been much discussion about whether the results achieved by radiotherapy are the same as those from cystectomy with, respect to achieving cure. We think that when one considers all types of bladder cancer, in the hands of a highly experienced urologist who specializes in this operation, cystectomy gives better results than radiotherapy. However, there are some patients, particularly those with other significant medical conditions, who will benefit from radiotherapy despite the possibility of a lower chance of permanent cure. In some centers, such as Massachusetts General Hospital, where the techniques of chemoradiotherapy and bladder preservation have been piloted, a urologist wall perform a cystoscopy about halfway through the planned course of radiotherapy. If the tumor is shrinking well, radiotherapy will be completed. However, if it appears that the cancer is not responding to radiotherapy, the plan wall be abandoned and replaced with a radical cystectomy.

Our use of the term or terms Actos Bladder Cancer is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Actos Bladder Cancer visit our site often.

Actos Bladder Cancer

Actos Bladder Cancer Important News

Actos Bladder Cancer : Sometimes an internal bladder connected to the urethra (the tube that carries urine to the outside of the body) isn’t possible and you will instead have a continent urinary diversion system. This means that you’ll have a pouch or reservoir, either external or more commonly internal, that collects your urine, and you’ll have to empty the pouch. This is also known as an ostomy or ileal conduit system.

The more common continent urinary diversion system is an internal reservoir, or pouch, made from a piece of intestine. The pouch is inside your body, but you must manually empty and flush the reservoir by inserting a syringe or catheter into a permanent ”hole” or stoma in your abdomen. Often the stoma is located unobtrusively in your navel, where it is not likely to be detected by a casual glance.

Your doctor, may, however, recommend an external pouch that is situated outside your body and attaches to your abdomen through a “hole” or stoma. You must manually empty the external pouch and cleanse the stoma. Either alternative sounds unpleasant, but having a pouch (particularly an internal reservoir) won’t interfere with your life or self-image as much as you might expect, if at all. You can still snorkel and swim. You can dance in a clingy, swingy dress or bike in Spandex shorts. You can do your job, whether it’s manning a drill press or managing a Fortune 500 company. And you can still look and feel sexy and enjoy a satisfying intimate relationship with your partner.

More information on Actos Bladder Cancer

One of the difficult issues for you and your medical team is to work out exactly what to do about the treatment of invasive bladder cancer. It is clear that cystectomy can be a life-saving procedure, yet many patients with invasive bladder cancer still eventually die of the disease, especially if it has penetrated the surrounding organs.

Your team will make a recommendation about treatment after carefully evaluating such very important factors as the extent of invasion by tumor cells (the stage), the normal or disorganized/abnormal appearance of die cancer cells under the microscope (grade), whether the cancer cells have invaded lymphatic channels or blood vessels, whether cancer cells are growing within the lymph nodes, and whether a specific cell control gene called P53 is normal.

If your cancer is organ-confined (i.e., if the cancer cells have not spread beyond the boundaries of the bladder and its immediate surrounding tissues), if it has not penetrated beyond the first layers of surrounding muscle, if there is no lymphatic or vascular invasion, and if lymph nodes are negative (i.e., they contain no cancer cells), the chance of permanent cure by cystectomy alone is around 80 percent.

Information from other sources on Actos Bladder Cancer

If, however, your cancer has penetrated deeply into the muscle or has a very poor level of cellular organization (high grade), if the P53 gene has mutated, or if invasion of lymphatic tissues or blood vessels (“lympho-vascular invasion”) is present, the chance of permanent cure may be much lower. In general, if things go badly after cystectomy, the problem is that cancer cells show themselves in other parts of the body (metastases) – a very dangerous situation. Over the past half-century, doctors have tried many approaches to improving the results, including the use of radiotherapy or the combination of radiotherapy and cystectomy. Neither of these approaches appears to have provided the solution.

Since the 1950s it has been known that cancer-killing drugs (chemotherapy) can sometimes shrink bladder cancer that has spread through the body, and sometimes they can completely eliminate the deposits of cancer in different parts of the body. In the past 25 years, several studies have looked at the impact of combining chemotherapy with cystectomy or with radiotherapy in an attempt to improve survival figures. Before that discussion, let’s talk a bit about chemotherapy.

Chemotherapy is a term that refers to the use of drugs to kill cancer cells. Chemotherapy is usually given by intravenous injection (injection by needle directly into the vein), but sometimes it can be administered as a tablet or even through a urinary catheter (intravesical) for a patient with superficial bladder cancer. (See Chapter 4.) There are many different types of chemotherapy, and a detailed discussion is beyond the scope of this book. Your medical team will talk with, you about what type of chemotherapy is best for you and why.

In brief, chemotherapy drugs mostly act to interfere with the ability of cancer cells to divide and multiply, often by inhibiting the function of enzymes within the cells or by blocking cell division and the formation of RNA and DNA, the substances of life. Because these drugs act on cells that are dividing and multiplying, they can also affect some normal tissues and thus can cause a range of side effects.

Our use of the term or terms Actos Bladder Cancer is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Actos Bladder Cancer visit our site often.

Actos Bladder Cancer

Actos Bladder Cancer News Flash

Actos Bladder Cancer : Bladder tumor “seeding” may occur during the procedure. As the tumors are resected, cancer cells are released into the irrigant which fills the bladder. These cells may implant in other areas of the bladder traumatized during the procedure. It should be understood that the bladder is generally filled with urine, and tumor cells can naturally implant at other locations even without surgery. Implantation can be lessened during surgery by avoiding injury to other bladder areas and by the use of adjuvant intravesical chemotherapy. There have been numerous studies over the past decade showing a number of chemotherapy agents can be effective in decreasing initial tumor recurrence, possibly by preventing seeding. Reduction in recurrence may however be short lived.

Previously, it was common practice to obtain multiple random bladder biopsies at the time of initial tumor resection. This was recommended to rule out the possibility of hidden CIS. Understanding these biopsy sites may increase the possibilities of tumor recurrence by tumor seeding, biopsies are now often limited to areas adjacent to the tumors removed and suspicious appearing areas only. CIS can be ruled out by using cytology, or by obtaining biopsies during future cystoscopy after the tumor has already been removed. When dealing with low grade tumors, random biopsies of the bladder will rarely show cancer.

After your procedure, depending on the level of anesthesia and the extent of surgery, you will be brought either to the recovery room or back to the area where you were first prepared for your procedure. You will be released to home only when you have fully recovered from you anesthetic and are doing well. The recurrence rate for superficial bladder cancer can be as high as 60-90%. Recurrences can cause bleeding and other difficulties and are best handled sooner rather than later. In addition, depending on the initial tumor grade and stage, progression to a more serious form of bladder cancer is an ongoing concern. Surveillance cystoscopy is therefore recommended. Cystoscopy is still the best means to check for recurrent disease. It is however, an invasive procedure and should be accomplished only as often as required. For solitary, low grade, non invasive disease, follow up cystoscopy can be accomplished with the flexible cystoscope if available. If negative at three months, further cystoscopic exams can be done yearly and eventually lengthened even further. For those with multiple tumors, large tumors, high grade tumors or those who also have CIS, frequent cystoscopies, initially every three months are called for. As long as there are no recurrences, the time between cystoscopies can be lengthened. Cytology can also be utilized to reduce the number of cystoscopies. If recurrence or progression does occur, heightened scrutiny is again called for.

More information on Actos Bladder Cancer

Adverse reactions are side effects of treatment. Approximately 95% of individuals will tolerate treatments well. Adverse reactions may be mild. Common reactions include cystitis (inflammation of the bladder characterized by burning on urination), hematuria, mild fever, malaise, and nausea. These symptoms generally pass without any treatment. For bothersome symptoms, various medications may prove helpful. Your physician can prescribe medication for burning or urinary frequency. For those with persistent cystitis, antibiotics can be utilized. For individuals experiencing severe symptoms lasting more than 48 hours, isoniazid, an anti-tuberculous drug can be prescribed.

A short course of 3 days, starting the day before the next dose of BCG can be used to prevent severe side effects. Fortunately severe reactions resulting in sepsis, a life threatening condition characterized by high fever, chills and drop in blood pressure, is exceedingly rare. Sepsis would be treated in a hospital with triple anti-tuberculous drugs, steroids, and broad spectrum antibiotics. There are other serious adverse reactions which may require dose reduction or discontinuation. These are all rare and include: inflammation of the prostate, persistent hematuria, hepatitis, inflammation of the testicles and or epididymis, bladder contraction, ureteral obstruction, joint pain or inflammation of the lungs.

Recurrence of bladder cancer after the initial induction course, or relapse after complete response, would indicate failure of therapy. When two or more courses result in recurrence or when recurrence develops during the first six to twelve months after induction and maintenance therapy, patients generally are felt to have disease which is at higher risk for progression. A high percentage of patients who are complete responders remain tumor free for up to five years. However, with the passage of more time, additional patients will have late recurrences. For those with late recurrences (two to three years after therapy), most will respond to repeat BCG therapy.

Information from other sources on Actos Bladder Cancer

Invasive bladder cancer is often recognizable to the urologist by its appearance during cystoscopy. These cancers are generally large, sometimes multi-focal, and solid in appearance as compared to the fine papillary appearance of superficial bladder cancers. During the transurethral resection of the tumor, the urologist can generally tell the tumor is invading into the deeper portions of the bladder wall.

The pathologist’s report will then indicate the grade of the cancer and the depth of invasion. If the tumor invades into muscle, it is an invasive tumor. Further staging would then include a CT Scan or MRI to assess local contiguous spread, lymph node spread, or more distant spread of the cancer. A chest X ray is also routine. If there are any suspicious areas, a CT Scan of the chest is ordered. A bone scan is generally not required unless the individual has had a new onset of bony pain that is not explained by injury or arthritis.

Our use of the term or terms Actos Bladder Cancer is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Actos Bladder Cancer visit our site often.

http://www.seedol.com

Actos Bladder Cancer Enlightenment

Actos Bladder Cancer : Apart from giving up smoking, follow-up is the best preventive meas­ure there is for bladder cancer. For the first two years after treatment, you’ll have a cystoscopy, usually every three to four months. If no further tumors are found during that time, follow-up every six months for an additional two years is usually adequate, with annual cystoscopies after that. Since bladder cancer can recur in later years, most doctors in the United States prefer to do annual follow-up cystoscopies for the rest of the patient’s life. Some physicians will reduce the number of cystoscopies by alternating them with the urine cytology test, whereby urine is collected and examined for the presence of can­cer cells under a microscope.

There is some discussion in the medical community about whether routine screening for blood in the urine might lead to earlier diagno­sis for those who are at high risk of recurrence. At present, these screening tests are not accurate enough to be completely reliable, but as technology advances, so will the sophistication of such tests, enabling people like you to monitor their disease more frequently and with far more comfort.

Many people claim that diet, antioxidants, and various other healthful lifestyle approaches are helpful in the battle against cancer or in retarding the progress of cancer. Frankly, the data are pretty thin, but we believe that it is a good idea to take regular exercise and con­sume a “heart-healthy” diet low in cholesterol and fats and high in whole grains, legumes, fruits, and vegetables. This doesn’t apply only to the battle against cancer; it just makes good sense when you’re try­ing to live a long and healthy life. In light of some of the published medical data, it is probably also a good idea to keep your fluid con­sumption up, as there is some evidence that bladder cancers occur less frequently in people who have high fluid intake.

More information on Actos Bladder Cancer

You may have a catheter in your urethra to help prevent bleeding or blockages. In that case, you may have to stay in the hospital for a day or two following surgery. (When possible, resection is performed on an outpatient basis.) If you are released the same day, your doctor should review possible after effects such as frequent urination, urine blockage, bladder infection, or blood in the urine and let you know what you should do if you experience any of them. Make sure you ask whether there are any restrictions on activity or exercise. Your doctor also should explain any risks, such as blood clots or perforation of the bladder.

There are numerous commercial brands of preparations used for immunotherapy and numerous treatment plans for administering them. You’ll want to know the details of the immunotherapy plan for you as well as what specific side effects (such as burning or chills and fatigue) are associated with the immunotherapy preparation you receive. Your doctor should tell you which members of your medical team to speak with if you experience ongoing problems or have con­cerns. Your doctor should tell you when to be concerned about side effects and what to do (e.g., make an office appointment or go to the emergency room).

Make sure that your doctor schedules a follow-up cystoscopy in about three months and discusses whether any of the newer screening tests for bladder-cancer “markers” might be appropriate for you. If you are still smoking, your doctor should encourage you to enroll in a program to help you quit. Make sure that your doctor reviews the symptoms that might signal a recurrence and discusses what you should do if you experience any of them.

Information from other sources on Actos Bladder Cancer

Cancer transforms everyone it touches; many cancer survivors describe their experience as a deep and motivating change. They find that what was “normal” during their pre-cancer lives no longer applies. Some say that life seems sweeter, that they are embracing life with a gusto and appreciation they didn’t have before. Others feel the shadow of worry that their cancer might return, and some are gripped by guilt that they survived cancer while others were not so lucky.

Sometimes cancer survivors are quick to view their personal tri­umph over their disease as a benchmark for handling anything that might come their way in life, including a recurrence. Others who nei­ther surge with confidence nor shake their fists at fate gradually return to a happier outlook, their faith in their health increasing along with hopes for the future. Being diagnosed with cancer often gives people the feeling that they have no control. Survivorship is all about learning to take control over how you live the rest of your life.

Our use of the term or terms Actos Bladder Cancer is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Actos Bladder Cancer visit our site often.

http://www.seedol.com

Actos Bladder Cancer Legal Broadcast

Actos Bladder Cancer : Recently, a number of clinical studies have demonstrated that in select individuals with muscle invasive bladder cancer, utilization of three modes of therapy can be effective in controlling invasive bladder cancer. These bladder preservation protocols have found those individuals that do best have smaller, invasive bladder cancers that can be completely resected. Resection is followed by radiation, which is then followed by chemotherapy. Those that fail the initial treatment go on to cystectomy. Long term bladder preservation in some studies is achieved in approximately 40%.

It should be noted however, this high rate of success may be contingent on choosing patients with less serious disease than the average patient undergoing cystectomy. Platinum based chemotherapy appears to offer the best results; however, the best combination regimen of chemotherapy is still being studied. Individuals with large, invasive canccrs and those with associated CIS or hydronephrosis secondary to cancer are not considered good candidates for bladder preserving therapy. Side effects of therapy are predominately the effects of chemotherapy, and include nausea, vomiting, diarrhea, fatigue, and sepsis secondary to lowered immunity.

After removal of the bladder, an approximately 6 inch piece of small intestine from the ileum (the final section of small intestine) is surgically separated from the rest of the small intestine. This section of bowel is used to create an ileal loop diversion. The ileum is the best section of small bowel to use since it has the lowest rate of electrolyte (body salts) disturbances afterwards. The ileum from which this section is removed is reconnected via suturing or staples.

More information on Actos Bladder Cancer

The future ileal loop is flushed clean and the base of the loop is sewn shut. The ends of both ureters are then carefully sewn to a small opening made close to the base of the ileal loop. The opposite end of the ileal loop is brought out through the skin and secured. The end of the loop is everted and tied down to the skin to create a raised stoma. Usually, small plastic tubes called stents are placed through the ileal loop, up the ureters, with their ends curling in the kidneys. These stents are temporary, generally left in for several weeks. Stents serve the purpose of decreasing urinary leakage at the anastomosis (the connection of the ureter to the ileal loop) and serve to allow the anastomosis to heal in an open fashion, thereby reducing the incidence of scarring. The ileal loop is the simplest and quickest form of urinary diversion. Post-operative complications are infrequent. Given these advantages, it remains the most common form of urinary diversion.

Although one can bring a ureter directly to the skin surface, it is generally not a good form of diversion. The ureters are flimsy, making them prone to obstruction if they are brought out directly. It may also be difficult to bring both ureters to the same place, thus necessitating two drainage bags. The ileal loop serves as a conduit and not a reservoir. The ureters are attached to it at its base. The ileal loop then traverses the skin and underlying tissues to allow unimpeded flow of urine. Urine flows continually through the loop and is collected in a bag attached over the exit of the loop, called the stoma.

Flernia: During the formation of an ileal loop or continent diversion, the ileal loop is brought out through a peritoneal opening, then through fascia (a thick supporting layer) out through the skin. If a gap exists or develops through the fascia, a parastomal hernia can develop. A hernia represents an abnormal pocket of peritoneum and possibly includes bowel. In addition, a hernia may develop through the surgical incision, which is called an incisional hernia. There is also a higher incidence of inguinal hernia (groin hernia) developing after surgery. Malnutrition, obesity, and lung diseases resulting in labored breathing all increase the risk for a hernia occurring. Many hernias require surgical correction.

Information from other sources on Actos Bladder Cancer

Kidney deterioration: If an individual faces recurrent urinary infections involving the kidneys, or has kidney stones, the kidneys may gradually lose function. Fortunately, this complication is rare. Your urologist will aggressively treat uninary infections, stones or deal with other complications which can impair kidney function.

Kidney stones: There is a small but real increased rate of kidney stones after an ileal loop diversion. Kidney stones are most often treated with ESWL (extracoporeal shock wave lithotripsy, a machine that can focus shock waves through the body to break up the stones).

Skin irritation: The skin surrounding the stoma and sometimes the skin beneath the collection bag may become reddened and irritated. By working with your enterostomy nurse, you will learn how to make your ostomy appliance more adherent. Sometimes, application of an ointment to the skin to protect it from the irritating effect of urine is required.

Stomal stenosis: Sometimes the stoma may be too tight, causing urine to pool in the ileal loop, leading to a urinary infection. This can be determined via a loopogram (an X ray study of the loop filled with contrast). Surgical correction of the loop is often required to resolve this problem.

Urinary infection: The ileal loop often can become colonized with bacteria. Colonization does not result in inflammation or any symptoms. However, bacteria may invade the wall of the ileal loop or travel up to the kidneys, resulting in infection. Symptoms may occur, including pain in the loop, kidney pain, blood in the urine, or increased sediment. A fever may occur, especially with kidney infection. To test for infection, urine is collected for culture directly from the loop. Appropriate antibiotics are then used to resolve the infection.

Our use of the term or terms Actos Bladder Cancer is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Actos Bladder Cancer visit our site often.

http://www.seedol.com

Actos Bladder Cancer

Actos Bladder Cancer :

Urothelial Cancer (UC)

A diagnosis of urothelial cancer (also known as transitional cell cancer) can mean many different things. Urothelial cancer is not a single type of cancer; it is classified by shape and whether it is restricted to the inner surface of the bladder (superficial to underlying tissues and muscle) or invasive, as well as by stage and grade of development.

The words transitional cells describe how the cells appear under the microscope. Transitional cells share features with various types of cells normally found near the bladder. Since 2009, pathologists have altered the common term to “urothelial cancer” to acknowledge the fact that all these cells arise from the lining of the ureters, bladder, and urethra, the urothelium.

 

More information on Actos Bladder Cancer

The human bladder is composed of several layers. On the innermost surface (which is next to where urine is stored) is a layer of cells known as the transitional cell epithelium. This layer varies in thickness from three to seven cells.

If your doctor described your tumor as being confined to the transitional cell epithelium, the tumor is a superficial tumor. About 74 percent of UCs are noninvasive and superficial when diagnosed, although superficial tumors may eventually progress to a more invasive stage. The word superficial has to be used carefully because it does not necessarily mean that the tumor is safe and doesn’t have a dangerous potential. In other words, some “superficial” tumors actually have a high malignant potential and the ability to spread elsewhere in the body.

A diagnosis of invasive UC means that the cancer has progressed into other layers of the bladder wall, such as the intermediate ceil layer or the muscle.

 

Information from other sources on Actos Bladder Cancer

Urothelial cancer is classified as either papillary or flat in shape, although and more than one kind of tumor may be present at the same time in the bladder.

Papillary tumors look like the fronds of a fern or a bunch of tiny berries or grapes. Papillary tumors can be superficial or invasive. Most papillary tumors are malignant; however, the papilloma tumor is a relatively benign type of papillary UC and is typically removed by surgery.

Other tumors appear to be flat and velvety and are more commonly called carcinoma in situ (CIS). These tumors are only one cell thick.

 

Our use of the term or terms Actos Bladder Cancer is for descriptive purposes only.  There is no relationship between the owners of this website and the maker of the product discussed in this post.  Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred.  Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls.  If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Actos Bladder Cancer visit our site often.

http://www.seedol.com

Actos Bladder Cancer

Actos Bladder Cancer :

Urothelial cancer, or UC (also referred to as transitional cell cancer or TCC). It can be localized on the surface or it may be invasive. (UC will be discussed in more detail later in this chapter.) UC is the most common type of bladder cancer, accounting for about 90 percent of all cases. In 2009, the American Cancer Society estimated that by the end of that year about 70,980 people would be diagnosed with bladder cancer—roughly 52,810 men and 18,170 women. About 63,882 of the cases would be urothelial cancer.

 

More information on Actos Bladder Cancer

Squamous cell cancer. This type of cancer accounts for about 4 percent of all bladder cancers and is usually an invasive cancer. Squamous means “resembling a scale” (which is flat and thin) or a scaly surface, and squamous cell cancer looks like skin cancer when viewed under a microscope. Among the causes of squamous cell development is the schistosomiasis parasite discussed in chapter 1.

Adenocarcinoma. ‘The appearance of this type of cancer closely resembles tumors of gland-forming cells in the intestinal tract. (,Adeno means “gland.”) It is often associated with the production of small amounts of mucus. Some adenocarcinomas occur in the urachus, a remnant of a fetal structure that connects the bladder to the umbilicus before birth. Adenocarcinomas, which are usually invasive, account for about 1 to 2 percent of bladder cancers.

In addition to the above types of bladder cancer, there are several extremely uncommon forms of the disease:

 

Information from other sources on Actos Bladder Cancer

*     Small cell anaplastic bladder cancer. Similar to small cell cancer, this rapidly growing cancer is usually found in the lung, and it shares a pattern of rapid growth and early spread to other parts of the body It is not really clear why small cell tumors arise in the bladder, although it is thought that they start from neuro-endocrine cells, isolated small, dark, round cells that arise during fetal development, of uncertain function, which are sometimes found in the bladder. These cells may play a part in the control of cellular growth.

  • Sarcomas and choriocarcinoma. It is quite rare for these two forms of cancer to be found in the bladder. Sarcomas are found in the muscle layers of the bladder. Choriocarcinoma is most often diagnosed among Asians in the Far East. Found in the bladder wall, it is an extremely rare tumor that seems to arise from small clusters of cells that paradoxically resemble part of the placenta.

 

Our use of the term or terms Actos Bladder Cancer is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Actos Bladder Cancer visit our site often.

http://www.seedol.com

Actos Bladder Cancer

Actos Bladder Cancer Page

 

Actos Bladder Cancer 12/20/2011: The elderly, frail individuals with multiple coexisting chronic illnesses, individuals that are weakened through mahiutrition or who have compromised immunity all would face substantially increased risk of complications from standard chemotherapy regimens for bladder cancer. Unfortunately, cisplatin is toxic to kidneys, and many individuals with bladder cancer have compromised kidney function which effectively rules out the use of platinum based chemotherapy. Other treatment regimens exist and are being worked on for these individuals, but none show the efficacy of the standard therapy which includes cisplatin.

Most individuals treated with standard chemotherapy regimens with metastatic bladder cancer will have recurrence and progression of their disease. Multiple treatment regimens have been utilized with overall response rates of 10-40%.[1] To date, regimens have generally used taxanes, both docetaxel and paclitaxel. Ifosfamide has been shown to have significant single agent activity as well, but is extremely toxic. Combination therapy with taxanes and ifosfamide are presently being tested.

For more information on Actos Bladder Cancer follow us on our RSS Feeds.

Our use of the Terms Actos Lawsuit ,Actos Side Effects is not intended to imply or insinuate that there is any relationship or connection between Best Legal Source and the maker of Actos. “Actos” is a trademark of its manufacturer, Takeda Pharmaceutical Company Limited. Best Legal Source is not the maker of Actos nor do we have any connection with Takeda Pharmaceutical Company Limited.

http://www.seedol.com

Actos Lawyer

Actos Lawyer Page

 

Actos Lawyers12/20/2011: There are multiple factors which must be considered. Generally younger patients, those in better overall health, and those with excellent preoperative erections can expect a more rapid return of erectile activity if the nerve sparing approach is successful. Even with meticulous nerve sparing, some nerve injury, either temporary or permanent may occur. The extent of the injury will determine how quickly erections may return. Erections may start returning in as little as two to three months, or may gradually return over a period of a year, or may not return at all.

For more information on Actos Lawyer follow us on our RSS Feeds.

Our use of the Terms Actos Lawsuit, Actos Bladder Cancer is not intended to imply or insinuate that there is any relationship or connection between Best Legal Source and the maker of Actos. Actos is a trademark of its manufacturer, Takeda Pharmaceutical Company Limited. Best Legal Source is not the maker of Actos nor do we have any connection with Takeda Pharmaceutical Company Limited.

http://www.seedol.com